IMAB I-MAB ADS (N Shares)

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab to Present at Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig.

I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.

Conference details are as follows:

Jefferies Global Healthcare Conference

Format: Fireside Chat and one-on-one meetings

Date: Thursday, June 5, 2025

Time: 3:45 PM ET

Webcast Link: Register

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit and follow us on and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors









EN
20/05/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). The Company’s American Deposi...

June 12, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series

I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Tuesday, June 17, 2025. The discussion will cover a general overview of the Claudin 18.2 landscape as a validated therapeutic target for gastric cancers. The session will also offer a ...

June 3, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab to Present at Jefferies Global Healthcare Conference ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig. I-Mab also recently announced that new data on givastomig has been accepted for a...

May 20, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Reports First Quarter 2025 Financial Results and Provides Busine...

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progressNew givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, SpainStrong financial position supported by $168.6 million of cash and cash equivalents, and short-term investments as of March 31, 2025; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., May 15, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (th...

May 15, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ...

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in Barcelona ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch